clinical trial · NCT04017962
A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection
CMVCMV InfectionHematopoietic Cell TransplantLetermovir Pillblood draw
brief summary
The purpose of this study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
started
Jul 19, 2019
primary completion
Aug 7, 2024
completion
Jul 29, 2025
last updated
Aug 11, 2025
official title
An Open-label, Single-arm Study of Letermovir (LTV) for Prevention of Recurrent CMV Infection in High-risk Hematopoietic Cell Transplant (HCT) Recipients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol